Journals / İnfeksiyon Dergisi / 2004 / Cilt: 18 - Sayı: 4

In vitro susceptibility of Helicobacter pylori strains to metronidazole, clarithromycin and amoxycillin

Helicobacter pylori suşlarının metronidazol, klaritromisin ve amoksisiline in vitro duyarlılıkları

Pages
473–476
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To succeed in eradicating H. pylori infections, the antibiotic resistance profiles of the regional strains should be determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study was to determine the in vitro susceptibility of Helicobacter pylori to the antimicrobials used in the treatment of its infection.
📊
Key Findings & Data:Strains of Helicobacter pylori isolated from gastric biopsies of 100 patients between years 2000 and 2002 were tested for their susceptibility to metronidazole, clarithromycin and amoxycillin with E test (AB Biodisk, Solna, Sweden).
💡
Conclusion & Impact:To succeed in eradicating H. pylori infections, the antibiotic resistance profiles of the regional strains should be determined.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

The purpose of this study was to determine the in vitro susceptibility of Helicobacter pylori to the antimicrobials used in the treatment of its infection. Strains of Helicobacter pylori isolated from gastric biopsies of 100 patients between years 2000 and 2002 were tested for their susceptibility to metronidazole, clarithromycin and amoxycillin with E test (AB Biodisk, Solna, Sweden). Resistances were 14% for metronidazole and 5% for clarithromycin. Resistance to 2 (metronidazole+clarithromycin) and 3 (metronidazole+clarithromycin+ amoxycillin) antimicrobials were 8% and 4%, respectively. The resistance rate of metronidazole was found low. On the other hand, the rate of amoxycillin resistant strains, at the same time resistant to metronidazole and clarithromycin, was high. To succeed in eradicating H. pylori infections, the antibiotic resistance profiles of the regional strains should be determined.

Özet

Bu çalışmanın amacı; Helicobacterpylortn'm, infeksiyonunun tedavisinde kullanılan antibiyotiklere in vitro duyarlılığını belirlemek idi. Mide biyopsisi örneklerinden izole edilen 100 tane H. pylori kökeninin E test yöntemi (AB Biodisk, Solna, İsveç) ile metronidazol, klaritromisin ve amoksisilin duyarlılıkları araştırılmıştır. İzole edilen suşların 31'i (%31) en az bir antibiyotiğe dirençli olarak bulunmuştur. Ondört H. pylori kökeni (%14) metronidazole, beşi (%5) klaritromisine dirençli olarak belirlenirken, sekizi (%8) metronidazol ve klaritromisine, dördü (%4) ise her üç antibiyotiğe de dirençli olarak belirlenmiştir. Çalışmada beklenen sonucun aksine; metronidazol direncinin düşük, bunun yanında tek başına amoksisilin direnci görülmemesine rağmen diğer iki antibiyotikle aynı anda görülen amoksisilin direncinin yüksek olduğu saptanmıştır. Helicobacter py/ori eradikasyonunun başarılı olabilmesi için o bölgeye ait kökenlerin antibiyotik direnç profillerinin'belirlenmesi önemlidir.

🔖

Cite This Article

BİNGÖL, R., KOLAYLI, F., ÇELEBİ, A., KARADENİZLİ, A. (2022). In vitro susceptibility of Helicobacter pylori strains to metronidazole, clarithromycin and amoxycillin. İnfeksiyon Dergisi, Cilt: 18 - Sayı: 4, 473–476. https://ajindex.com/articles/546567

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis and peptic ulceration. J Clin Pathol 1986; 39:353-65
  2. Blaser MJ, Perez-Perez Gl, Kleanthous H. Infection with Helicobacter pylori strains possessing cagA associated with an increasing risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55:2111 -5
  3. Foreman D and Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993; 341:359-62
  4. National Institutes of Health. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease: Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9
  5. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-41. 6. van der Hulst RWM, Rauws EAJ, Köycü B, et al. Prevention of ulcer recurrence after successful eradication of Helicobacter pylori infection: prospective long term follow up study. Gastroenterology997; 113:1082-6
  6. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European Multicentre Survey of in vitro Antimicrobial Resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3
  7. Forbes BA, Sahm DF, Weissfeld AS, eds. Bailey & Scott's Diagnostic Microbiology. 11 th ed. Missouri: Mosby Co, 2002: 474-81 9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Eleventh Informational Supplement. M100-S11. Villanova, PA: NCCLS, 1997
  8. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxicillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 67-70
  9. Debets-Ossenkopp YJ, Herscheid AJ, Pot RGJ, Kuipers EJ, Kusters JG, Vanderbroucke-Grauls. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and travofloxacin in the Netherlands. J/AC1999; 43: 511-5
  10. Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54:207-16»
  11. Engin D, Erciş S, Özarslan E, et al. Antibiotic susceptibilities of Helicobacter pylori strains isolated in Turkey [Abstract]. Int J Med Microbiol 2001; 291 (Suppl 31): 16
  12. Sharara Al, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002; 19:155-8
  13. Pilotto A, Ras